Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

Arcus Biosciences Announces New Employment Inducement Grants


Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted eight new employees options to purchase a total of 33,200 shares of the Company's common stock at an exercise price per share of $18.66, which was the closing price on September 25, 2023, and restricted stock units to acquire a total of 16,600 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 A2a/A2b receptors) and HIF-2?. For more information about Arcus Biosciences' clinical and preclinical programs, please visit www.arcusbio.com.

Inducement PR

Source: Arcus Biosciences


These press releases may also interest you

at 00:45
Revenues -5% yoy organic TDA, -3% yoy organic, a solid result given market conditions, high comparison base; volumes stabilisingBy GBU, Adecco -5%, with good results across Asia, Iberia, EEMENA, LatAm outweighed by challenging markets, particularly...

at 00:07
The pilot aims to speed up the process for safely and securely finding participants for UK clinical trials, improving efficiencies and opportunities for people to take part in research and access innovative new medicines. The pilot will test a new...

4 nov 2024
BioCity Biopharma (BioCity) announced late-breaking results of the 2-SUCCEED clinical trial of SC0062, a selective endothelin receptor type A (ETA) antagonist, for the treatment of IgA Nephropathy (IgAN). These results were presented at the Oral...

4 nov 2024
Kenvue Canada Inc., a division of Kenvue Inc. ("Kenvue"), the world's largest pure-play consumer health company by revenue and maker of iconic brands such as Tylenol®, Aveeno, Listerine® and Neutrogena®, announced the completion of its newly...

4 nov 2024
Hugel Inc., a leading global medical aesthetics company, said on Tuesday that WELLAGE, its clinical derma cosmetics brand for skin wellness, joined the festival K-beauty Boost in NYC 2024 at the Korean Cultural Center New...

4 nov 2024
Acoustiic Inc. has received a research funding agreement from the Focused Ultrasound Foundation (FUS) to adapt their WaveMatrixtm platform to explore the therapeutic applications of ultrasound in companion animals. Acoustiic's platform provides an...



News published on and distributed by: